Astrazeneca’s Target Innovation Programme - Biowebspin | Biowebspin
Logo Biowebspin

Biowebspin : THE #1 ACADEMIA-INDUSTRY PARTNERING NETWORK IN LIFE SCIENCES

The worldwide platform to find industrial partners and funding

External open innovation partner programAstrazeneca’s Target Innovation Programme

Do you have an innovative idea for a drug discovery project? This may be a new drug target, or a new mechanism for a known target. Are you interested in partnering with AstraZeneca to help validate your target and translate your novel science into a new medicine?

What we are looking for

AstraZeneca, through its Target Innovation Program, would like to enable your screening for the exploration and validation of attractive, novel drug targets, and novel mechanisms of modulating known targets. In this call we are focusing on chronic lung diseases (asthma, COPD, etc).

Phenotypic as well as molecular target screening proposals, and proposals for accessing fragment-screening libraries, are welcome.

What we offer

The programme aims to foster innovative partnerships between AstraZeneca and novel science at academic or other research organizations, to advance target validation for your exciting new target ideas. Collaborative proposals can gain access to a diversity screening subset library of up to 250,000 compounds, phenotypic and fragment screening sets and/or the performance of a full high-throughput screen.

What to submit

Applying under this programme is straightforward. A short online submission form will guide you in completing your proposal. While AstraZeneca will not share the information beyond its own staff, your proposal should contain only non-confidential information.

The submission should include:

  • The therapeutic area
  • Brief description of the target/pathway
  • Hypothesis
  • Screening proposal
  • Proposed next steps to validate your approach
How does it work

Each application is read and reviewed by experienced scientists who are committed to evaluate your proposals. You can expect to receive feedback within ten weeks of the submission of a proposal. Content of the initial proposals should be non-confidential. If you want to share confidential data or knowledge with us to further explain your proposal, please let us know in your application and we can if required set up appropriate arrangements after the initial review phase. The decision on which targets receive HTS access, and/or compound libraries is made at the sole and absolute discretion of AstraZeneca.

Privacy, confidentiality & FAQ
Astrazeneca

While AstraZeneca will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.

If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA) and to confirm ability to execute a Materials Transfer Agreement (MTA).

Biowebspin

Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.

Biowebspin is a matchmaking platform between academia & industry. Biowebspin is not involved in the IP discussion and is not charging any success or license fees. Your «Open Innovation» opportunities on Biowebspin are only visible by industrials and the Biowebspin team. You can remove your data at any time. Biowebspin strongly recommends that you do not enter any confidential data or if you do so, that your technology transfer office agrees the submission of your pre-proposal on Biowebspin. If you directly submit your pre-proposal on an industrial partner website, you will agree their terms, conditions and privacy policy of our industrial partner website. Biowebspin is not responsible for the content, accuracy, or opinion of its industrial partner website.

As a Swiss International company, Biowebspin has high standard security and privacy system. Biowebspin is in accordance with the Federal Data Protection and Information Commissioner. Check here the terms and conditions of the matchmaking service of Biowebspin.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that spans the discovery, development, manufacturing, distribution and worldwide commercialisation of primary care and speciality care medicines.

About Biowebspin:

Biowebspin is the #1 academia-industry partnering network in Life Sciences.
For academics, Biowebspin is the platform to find industrial partners and funding for their research projects matching R&D programs of more than 500 leading Life Sciences companies and foundations.

Check if one program will fit your researches for industrial collaboration and funding